MUC1 and non-small cell lung carcinoma: In a phase II/III randomized, double-blind study testing stage IV NSCLC patients lacking an EGFR mutation while also expressing ≥ 50% of MUC1 on tumor cell surface, 222 patients received standard first-line chemotherapy in combination and without combination of TG4010 vaccine (39).